A multicenter, double-blind, randomized, parallel groups placebo-controlled study to assess the efficacy and safety of fexofenadine 120mg BID in subjects with mild to moderate persistent asthma.

Trial Profile

A multicenter, double-blind, randomized, parallel groups placebo-controlled study to assess the efficacy and safety of fexofenadine 120mg BID in subjects with mild to moderate persistent asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Fexofenadine (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Aventis Pharmaceuticals
  • Most Recent Events

    • 20 Aug 2008 Primary and secondary endpoints added as reported by ClinicalTrials.gov.
    • 20 Aug 2008 Actual initiation date changed from Jan 2002 to Feb 2002 as reported by ClinicalTrials.gov.
    • 20 Aug 2008 Actual end date (Oct 2003) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top